ABN AMRO Bank N.V. Takes $21.52 Million Position in Quest Diagnostics Incorporated $DGX

Key Points

• ABN AMRO Bank N.V. acquired 101,667 Quest Diagnostics shares during the second quarter, worth approximately $21.52 million, while institutional investors collectively own 88.06% of the company.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $235.31. Several firms recently raised their price targets, including Mizuho to $260 and JPMorgan to $250.
• Quest Diagnostics exceeded quarterly expectations, reporting $3.12 EPS and $3.04 billion in revenue, up 10.2% year over year. The company also declared a quarterly dividend of $0.86 per share, representing an annualized yield of about 1.5%.

ABN AMRO Bank N.V. purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 101,667 shares of the medical research company's stock, valued at approximately $21,524,000. ABN AMRO Bank N.V. owned about 0.09% of Quest Diagnostics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in Quest Diagnostics during the 2nd quarter worth approximately $1,054,000. One Wealth Advisors LLC bought a new position in shares of Quest Diagnostics during the second quarter valued at $298,000. Clearstead Trust LLC acquired a new position in shares of Quest Diagnostics during the second quarter worth $200,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Quest Diagnostics during the second quarter worth $336,000. Finally, Bryn Mawr Trust Advisors LLC bought a new stake in shares of Quest Diagnostics in the second quarter worth $484,000. Institutional investors own 88.06% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Mizuho raised their target price on Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a "buy (b+)" rating to a "buy (a-)" rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on Quest Diagnostics from $220.00 to $250.00 and gave the company a "neutral" rating in a research note on Tuesday, July 28th. UBS Group raised their price objective on Quest Diagnostics from $220.00 to $232.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $235.31.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Insider Activity

In related news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company's stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares of the company's stock, valued at approximately $2,430,585.30. The trade was a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock worth $3,947,088 over the last quarter. 0.88% of the stock is currently owned by corporate insiders.

Quest Diagnostics Trading Down 0.7%

DGX opened at $234.48 on Friday. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $240.13. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The company has a market cap of $25.88 billion, a P/E ratio of 24.89, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company has a fifty day moving average price of $215.60 and a two-hundred day moving average price of $203.18.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company had revenue of $3.04 billion for the quarter, compared to analysts' expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $2.62 EPS. The business's revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics's payout ratio is currently 36.52%.

Quest Diagnostics Company Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source